Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ESMO congress

Novartis drug effective in hard-to-treat psoriasis

Secukinumab to commence phase III trials

Novartis building

Novartis heart failure candidate clears phase III trial

Serelaxin proves effective in reducing all-cause mortality

Novartis building

CHMP backs trio of Novartis products

Including two diabetes drugs and one for non-cancerous kidney tumours

Novartis building

Novartis signs $665m option deal with Selexys

Would acquire biotech company and its sickle cell disease drug

- PMLiVE

Roche plans translational research centre in New York

Follows plan to close New Jersey headquarters

- PMLiVE

Roche loses Indian Tarceva patent battle with Cipla

As Novartis' Glivec patent law challenge begins again

Roche - Basel

Roche says pipeline will balance cancer drug patent losses

Has 11 new molecular entities in late-stage portfolio and 11 line extensions

Novartis building

FDA panel backs Novartis’ updated cystic fibrosis drug

New version of inhaled tobramycin therapy is simpler to use

Novartis building

Novartis showcases COPD candidates at ERS meeting

Positive results for three late-stage drugs

Novartis reaffirms commitment to UK respiratory research site

Will slim down and redevelop Horsham facility

- PMLiVE

Novartis eye drug Jetrea effective in phase III

Pharma company and its partner ThromboGenics report positive trial data

Novartis day

Novartis signs cancer immunotherapy deal with Penn

R&D alliance with the University of Pennsylvania will focus on novel T-cell immunotherapies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links